Clinical research, explained by its authors.
JAMA Network is a collection of specialty author interviews built around newly published clinical studies, reviews, and viewpoints. Episodes move patiently from research question to method, result, and practical meaning, with hosts pressing authors to define terms and clarify limits.
PRESS PLAY
JAMA Network is a broad medical interview feed built from conversations with authors of recent JAMA specialty journal articles. Its strength is structure. Episodes usually begin with a focused clinical problem, then move into why the authors asked the question, how the study was assembled, and what the findings can reasonably support. The pace is measured. Hosts often pause on terminology, trial design, or a statistical adjustment so that the result does not float free from the method that produced it. That makes the show especially good for listeners who want more than a headline but less than a full journal club. The range is wide. Recent episodes cover opioid withdrawal and autonomic regulation, geographic atrophy, incisional hernia prevention after abdominal midline closure, appendiceal tumors that may be missed when appendicitis is treated with antibiotics alone, retinal disease prevalence and disparities, federal research funding, and novel treatment work in recurrent or metastatic adenoid cystic carcinoma. The conversations are not glossy. They are clinical, cautious, and specific. A guest may explain heart rate variability, baseline lesion area, open-label trial conditions, or low-code tools for research prototyping, then restate the point in more accessible terms. The show also has a recurring habit of separating signal from excitement. Psychedelic therapy, yoga interventions, artificial intelligence, and new cancer treatments are discussed with interest, but the episodes keep returning to sample sizes, replication, endpoints, and limitations. That restraint is part of the appeal. It respects both the promise of new research and the burden of proof required in medicine. The tone can be warm, but it is never chatty. Listeners hear professional curiosity, a concern for patient consequences, and a clear preference for evidence over posture. For clinicians, researchers, trainees, and serious health-policy observers, JAMA Network functions as a disciplined audio companion to the journals themselves.
Made for: Suited to clinicians, researchers, medical trainees, and evidence-minded health listeners who want careful context around new specialty studies. It also serves non-specialists comfortable with technical language when it is translated step by step.
What sets it apart: The show keeps the author close to the evidence while the interviewer keeps the listener oriented. It stands apart by treating methods, limitations, and clinical implications as the center of the story, not as footnotes.
Audio Interviews with Authors of articles in the JAMA Network Specialty Journals
Based on 5 episodes we listened to · September 2026
Clinical findings become more legible through careful questions about trial design, effect size, interpretation, and limits.
JAMA Network turns newly published clinical research into direct, methodical conversations between journal editors and study authors. The range runs from depression treatment and school-based mindfulness to opioid withdrawal, focal epilepsy, and geographic atrophy.
A promising treatment enters; study design checks its ID at the door.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A clear look at yoga as a possible add on during opioid withdrawal.
The episode treats yoga as a possible add on during opioid withdrawal, where symptoms can be severe and relapse risk stays high. It stays close to the randomized trial and moves through the study design, the yoga sessions, and the reported outcome without losing the thread.
A careful look at how similarly geographic atrophy advances in paired eyes.
Geographic atrophy in paired eyes does not move in lockstep, and this piece makes that plain without overselling the result. It starts from a long-held assumption, then turns to a pre-specified post-hoc analysis of ARIDS 2, including transformed rates because raw enlargement can…
A clear look at how blinding shapes depression treatment results.
Psychiatric treatment gets a useful reality check here: the point is not a simple race between psychedelics and antidepressants, but an equal-blinding comparison shaped by what trial participants knew about what they received.
A careful look at mindfulness prediction that finds signal without pretending it settles the clinical question.
It asks a practical question with real stakes: whether machine learning can help identify which adolescents are most likely to benefit from school-based mindfulness, and whether that kind of prediction matters in practice.
Jonquilyn Hill chases one listener question per episode to the experts who can answer it.
Hard conversations, patiently held, with room to laugh.
Fearne Cotton interviews guests like Boy George and Bryony Gordon about mental health and identity.
Dr. Joy Harden Bradford pairs therapy insight with Black TV recaps, maternal health, and history.
This episode features an interview with Dr.
The episode looks at yoga as an add-on treatment for opioid withdrawal.
Neil Bressler talks with Dr.
This episode discusses a randomized clinical trial comparing small bites versus large bites for closing abdominal midline incisions to prevent incisional hernias, featuring interviews with the study authors.
This episode features an interview with Dr.
Authors discuss the oncologic risk of missed appendiceal tumors when treating acute appendicitis with antibiotics alone.
An interview with Dr.
JAMA Psychiatry Author Interviews looks at a new meta-analysis comparing psychedelic therapy with antidepressants for depression in an equal-unblinding meta-analysis.
An interview with Dr.
An interview with authors of a study on eliminating race-based algorithms in kidney transplant waitlist time calculations.
An interview with a virologist discussing how Epstein-Barr virus antibodies can help differentiate multiple sclerosis from other neuroinflammatory diseases.
An interview with Dr.
Authors discuss a randomized clinical trial on once-weekly semaglutide for alcohol use disorder, exploring GLP-1 drugs' potential beyond weight loss.
An interview with a dermatologist discussing a study on the cost of sunscreen use and its implications for skin cancer prevention.
Dr.
Cenobamate produced stronger seizure outcomes, but nearly 60% of patients reported side effects.
This episode discusses a JAMA Dermatology study on the discordance between clinician and patient assessments of treatment response in chronic graft-versus-host disease (GVHD) and its implications for patient care.
An interview with a dermatologist discussing research on advanced practice clinicians' role in prescribing specialty medications and its impact on drug spending trends.
An interview with Professor Tian Wang discussing a post-hoc analysis of the PULSAR trial on different aflibercept doses for polypoidal choroidal vasculopathy.
This JAMA Psychiatry podcast episode discusses a new randomized clinical trial on tailored weight loss programs for adults with serious mental illness, exploring health risks and innovative approaches to address cardiovascular disease and obesity in this population.
This episode features an interview with authors of a randomized trial comparing biofeedback versus respiratory retraining for inducible laryngeal obstruction.
Interview with authors of a study on metastatic recurrence among adolescents and young adults with cancer in California.
This JAMA Neurology podcast episode features an interview with Dr.
An interview with Dr.
Host Dr.
An interview with Dr.
Authors discuss a study on long-term physical activity and digestive system cancer risk, emphasizing consistency over intensity.
This JAMA Psychiatry interview discusses a new randomized controlled trial on serial ketamine infusions as an adjunctive therapy for depression in inpatient settings, focusing on methodological rigor and comparisons with esketamine.
Interview with authors of new guidelines for managing benign breast fibroepithelial lesions.
An interview with Dr.
An interview with a researcher about a study linking soft drink consumption to depression via gut microbiome changes.
An interview with Dr.